The difference in pharmacokinetics of mitomycin C, given either as a single agent or as a part of combination chemotherapy

J. Verweij, M. Stuurman, J. de Vries, H. M. Pinedo

Research output: Contribution to journalArticlepeer-review

Abstract

In a previous report it was suggested that the total body clearance of mitomycin C (MMC) was different after single agent treatment compared to combination chemotherapy. This suggestion was based on recalculations to one dose level. In the present study a fixed dose of 10 mg/m2 was used. Seven patients on single agent MMC and eight on combination chemotherapy were studied. Terminal half-life varied from 25 to 78 mm, volume of distribution from 7 to 73 l/m2, total body clearance from 11 to 56 l/h per m2, and area under the plasma concentration-time curve (AUC) from 177 to 933 μg/h per 1. Total body clearance was significantly higher and AUC significantly lower in patients on combination chemotherapy. The cause of this difference was not investigated.

Original languageEnglish (US)
Pages (from-to)283-284
Number of pages2
JournalJournal of Cancer Research and Clinical Oncology
Volume112
Issue number3
DOIs
StatePublished - Nov 1986
Externally publishedYes

Keywords

  • Combination chemotherapy
  • Mitomycin C
  • Pharmacokinetics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The difference in pharmacokinetics of mitomycin C, given either as a single agent or as a part of combination chemotherapy'. Together they form a unique fingerprint.

Cite this